SYRS (Syros Pharmaceuticals, Inc) גידול ברווח למניה בשנה הנוכחית

The basis of the analysis is the R&D foundation of Syros Pharmaceuticals (SYRS) in the US, which creates tools for the precise control of gene expression. The annual growth rate of earnings per share visualizes the dynamics of this process, where 0.00 is recorded as the baseline value. Diversification of oncology research reduces the risk of test failures, yet a severe management crisis and debt default place the company in survival mode.

For the biopharmaceutical startup Syros Pharmaceuticals (SYRS), which focuses on high-cost R&D in oncology, this indicator serves as a measure of capital management efficiency. The relative EPS YoY dynamics are calculated as the percentage deviation of current earnings per share from the previous year's figures, neutralizing short-term market noise. Growth in this parameter confirms the company's ability to optimize innovation costs while minimizing the risks of deep capital drawdowns.